Danaher Corporation (DHR)

NYSE
Currency in USD
190.85
+3.03(+1.61%)
Real-time Data·
DHR Scorecard
Full Analysis
Management has been aggressively buying back shares
DHR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
180.19191.07
52 wk Range
171.00281.70
Key Statistics
Edit
Prev. Close
187.82
Open
187.39
Day's Range
180.19-191.07
52 wk Range
171-281.7
Volume
4.91M
Average Volume (3m)
4.39M
1-Year Change
-27.56%
Book Value / Share
71.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DHR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
247.05
Upside
+29.45%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Danaher Corporation Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Danaher Corporation SWOT Analysis


Bioprocessing Boom
Danaher's strong position in bioprocessing and life sciences drives growth, with analysts projecting high single-digit core revenue expansion and margin improvements
Diagnostic Frontie
Explore Danaher's strategic investments in emerging diagnostic areas, including companion diagnostics and multiplex expansion on the GeneXpert platform
Market Challenges
Delve into Danaher's navigation of persistent headwinds in non-Biopro segments and uncertainties in the Chinese market, impacting future growth prospects
Financial Outlook
Analysts project EPS growth from $7.49 in FY2024 to $8.36 in FY2025, with price targets ranging from $275 to $311, reflecting market confidence
Read full SWOT analysis

Danaher Corporation Earnings Call Summary for Q1/2025

  • Danaher beats Q1 2025 estimates: EPS $1.88 vs $1.62 forecast, revenue $5.74B vs $5.56B expected; stock jumps 5.1% in premarket
  • Core revenue flat YoY; company targets $150M cost savings via restructuring; China market sees high single-digit decline
  • Full-year 2025 guidance: ~3% core revenue growth, adjusted EPS $7.60-$7.75; Q2 expects low single-digit core revenue growth
  • Strong financial health: 61.2% gross margin, $1.1B free cash flow; 33-year dividend track record, 7 years of consecutive growth
  • CEO emphasizes market strength; CFO notes strategic flexibility amid evolving landscape and potential market opportunities
Last Updated: 22/04/2025, 11:26 pm
Read Full Transcript

Compare DHR to Peers and Sector

Metrics to compare
DHR
Peers
Sector
Relationship
P/E Ratio
36.3x−1.4x−0.5x
PEG Ratio
−2.850.070.00
Price/Book
2.7x1.3x2.6x
Price / LTM Sales
5.7x4.6x2.9x
Upside (Analyst Target)
28.4%37.5%51.4%
Fair Value Upside
Unlock32.0%9.5%Unlock

Analyst Ratings

24 Buy
3 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 247.05
(+29.45% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.19%
Dividend Yield
0.68%
Industry Median 0.71%
Annualised payout
1.28
Paid quarterly
5-Years Growth
+10.37%
Growth Streak

Earnings

Latest Release
Apr 22, 2025
EPS / Forecast
1.88 / 1.62
Revenue / Forecast
5.74B / 5.56B
EPS Revisions
Last 90 days

People Also Watch

100.66
VLTO
+1.21%
519.44
SPGI
+1.47%
174.50
ICE
+1.49%
100.31
CCI
+2.12%
100.36
UPS
+0.71%

FAQ

What Is the Danaher (DHR) Stock Price Today?

The Danaher stock price today is 190.85

What Stock Exchange Does Danaher Trade On?

Danaher is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Danaher?

The stock symbol for Danaher is "DHR."

Does Danaher Pay Dividends? What’s The Current Dividend Yield?

The Danaher dividend yield is 0.68%.

What Is the Danaher Market Cap?

As of today, Danaher market cap is 136.59B.

What Is Danaher's Earnings Per Share (TTM)?

The Danaher EPS (TTM) is 5.19.

When Is the Next Danaher Earnings Date?

Danaher will release its next earnings report on 28 July 2025.

From a Technical Analysis Perspective, Is DHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.